5-chloro-2-isopropyl-1H-indole | 573716-61-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: 5-chloro-2-isopropyl-1H-indole
• 英文别名: 5-chloro-2-isopropylindole；1H-Indole, 5-chloro-2-(1-methylethyl)-；5-chloro-2-propan-2-yl-1H-indole
• CAS: 573716-61-7
• 化学式: C₁₁H₁₂ClN
• 分子量: 193.676
• InChiKey: YYRJXVNEZQLQKS-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.4
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.27
• 拓扑面积：
  15.8
• 氢给体数：
  1
• 氢受体数：
  0

反应信息

• 作为反应物：
  描述：

  5-chloro-2-isopropyl-1H-indole 、 4-哌啶酮 在 磷酸 、 溶剂黄146 作用下， 生成 1h-Indole,5-chloro-2-(1-methylethyl)-3-(1,2,3,6-tetrahydro-4-pyridinyl)-
  参考文献：
  名称：

  2-Alkyl-3-(1,2,3,6-tetrahydropyridin-4-yl)-1H-indoles as novel 5-HT6 receptor agonists

  摘要：

  A series of 2-alkyl-3-(1,2,3,6-tetrahydropyridin-4-yl)-1H-indoles were synthesized and evaluated for their 5-HT6 activity. The most potent agonist in this series was 5-chloro-2-methyl-3-(1,2,3,6-tetrahydropyridin-4-yl)-1H-indole with an IC50 = 7.4 nM in H-3-LSD binding and an EC50 = 1.0 nM in a functional assay measuring production of cyclic AMP. (c) 2005 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2005.06.067
• 作为产物：
  描述：

  4-氯-2-甲基苯胺 在 仲丁基锂 、 三氟乙酸 作用下， 以 四氢呋喃 、 二氯甲烷 为溶剂， 反应 2.0h， 生成 5-chloro-2-isopropyl-1H-indole
  参考文献：
  名称：

  2-Alkyl-3-(1,2,3,6-tetrahydropyridin-4-yl)-1H-indoles as novel 5-HT6 receptor agonists

  摘要：

  A series of 2-alkyl-3-(1,2,3,6-tetrahydropyridin-4-yl)-1H-indoles were synthesized and evaluated for their 5-HT6 activity. The most potent agonist in this series was 5-chloro-2-methyl-3-(1,2,3,6-tetrahydropyridin-4-yl)-1H-indole with an IC50 = 7.4 nM in H-3-LSD binding and an EC50 = 1.0 nM in a functional assay measuring production of cyclic AMP. (c) 2005 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2005.06.067

文献信息

• INDOLE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF
  申请人：Tatani Kazuya

  公开号：US20120129890A1

  公开（公告）日：2012-05-24

  A compound (I) of the present invention, which has an EP 1 receptor antagonism: [wherein A represents a benzene ring or the like; Y 1 represents a C 1-6 alkylene group; Y 2 represents a single bond or the like; R 1 represents a hydrogen atom, a C 1-6 alkyl group or the like; R 2 represents a phenyl group which may have a substituent, a 5-membered aromatic heterocyclic ring which may have a substituent, a 6-membered aromatic heterocyclic ring which may have a substituent or the like; R 3 represents a halogen atom, a C 1-6 alkoxy group or the like; R 4 represents a hydrogen atom or the like; and R 5 represents a hydrogen atom or the like] or a pharmaceutically acceptable salt thereof is provided. Furthermore, the compound (I) of the present invention can be used as an agent for treating or preventing LUTS, in particular, various symptoms of OABs.

  本发明提供了一种具有EP1受体拮抗作用的化合物（I）[其中A代表苯环或类似结构；Y1代表C1-6烷基亚基；Y2代表单键或类似结构；R1代表氢原子、C1-6烷基团或类似结构；R2代表可能含有取代基的苯基、可能含有取代基的5元芳香杂环、可能含有取代基的6元芳香杂环或类似结构；R3代表卤素原子、C1-6烷氧基团或类似结构；R4代表氢原子或类似结构；R5代表氢原子或类似结构]或其药物可接受的盐。此外，本发明的化合物（I）可用作治疗或预防LUTS的药物，特别是OAB的各种症状。
• Substituted indoles as alpha-1 agonists
  申请人：——

  公开号：US20030220319A1

  公开（公告）日：2003-11-27

  This invention relates to compounds which are alpha-1 receptor agonists, preferably alpha-1A/L receptor agonists, and which are represented by Formula I: 1 wherein X is —S(O) n — or —C(O)—, A is C 1-6 alkyl, aryl, heteroaryl, hydroxyalkyl, or —(CH 2 ) p —NR a R b , and the other substituents are as defined in the specification; or individual isomers, racemic or non-racemic mixtures of isomers, or pharmaceutically acceptable salts or solvates thereof. The invention further relates to pharmaceutical compositions containing such compounds, methods for their use as therapeutic agents, and methods of preparation thereof.

  这项发明涉及α-1受体激动剂，优选为α-1A/L受体激动剂，其化学式如下：其中X为—S(O)n—或—C(O)—，A为C1-6烷基，芳基，杂环芳基，羟基烷基，或—(CH2)p—NRaRb，其他取代基如规范中所定义；或其各个异构体，消旋体或非消旋体混合物，或其药用盐或溶剂化合物。该发明还涉及含有这类化合物的药物组合物，以及它们作为治疗剂的使用方法和制备方法。
• [EN] POTENT AND SELECTIVE MU OPIOID RECEPTOR MODULATORS<br/>[FR] MODULATEURS PUISSANTS ET SÉLECTIFS DES RÉCEPTEURS OPIOÏDES MU
  申请人：UNIV VIRGINIA COMMONWEALTH

  公开号：WO2017200970A1

  公开（公告）日：2017-11-23

  Analogues of 6 α/β-naltrexamine (NAQ) are provided. The analogues are selective, reversible antagonists of the mu opioid receptor (MOR) that exhibit good blood brain barrier penetration. The compounds are used in the treatment of opioid addiction and other diseases and conditions, including for the treatment of pain.

  提供了6个α/β-纳曲酮胺（NAQ）的类似物。这些类似物是选择性、可逆的μ阿片受体（MOR）拮抗剂，具有良好的血脑屏障穿透性。这些化合物用于治疗阿片类药物成瘾和其他疾病和症状，包括用于疼痛治疗。
• Indole derivative or pharmaceutically acceptable salt thereof
  申请人：Tatani Kazuya

  公开号：US08680120B2

  公开（公告）日：2014-03-25

  A compound (I) of the present invention, which has an EP1 receptor antagonism: [wherein A represents a benzene ring or the like; Y1 represents a C1-6 alkylene group; Y2 represents a single bond or the like; R1 represents a hydrogen atom, a C1-6 alkyl group or the like; R2 represents a phenyl group which may have a substituent, a 5-membered aromatic heterocyclic ring which may have a substituent, a 6-membered aromatic heterocyclic ring which may have a substituent or the like; R3 represents a halogen atom, a C1-6 alkoxy group or the like; R4 represents a hydrogen atom or the like; and R5 represents a hydrogen atom or the like] or a pharmaceutically acceptable salt thereof is provided. Furthermore, the compound (I) of the present invention can be used as an agent for treating or preventing LUTS, in particular, various symptoms of OABs.

  本发明提供了一种具有EP1受体拮抗作用的化合物(I)：[其中，A代表苯环或类似物；Y1代表C1-6烷基；Y2代表单键或类似物；R1代表氢原子，C1-6烷基或类似物；R2代表苯基，可以有取代基，也可以是5-成员芳香族杂环环，可以有取代基，也可以是6-成员芳香族杂环环，可以有取代基或类似物；R3代表卤素原子，C1-6烷氧基或类似物；R4代表氢原子或类似物；R5代表氢原子或类似物]或其药学上可接受的盐。此外，本发明的化合物(I)可以用作治疗或预防下尿路症状，特别是膀胱过度活动症的各种症状的药物。
• Glucagon Receptor Antagonist Compounds, Compositions Containing Such Compounds And Methods Of Use
  申请人：Kim Ronald M.

  公开号：US20090209564A1

  公开（公告）日：2009-08-20

  Glucagon receptor antagonist compounds are disclosed. The compounds are useful for treating type 2 diabetes and related conditions. Pharmaceutical compositions and methods of treatment are also included.

  本文披露了一种胰高血糖素受体拮抗剂化合物。这些化合物可用于治疗2型糖尿病及相关疾病。同时还包括制药组合物和治疗方法。